Strategic Partnership Pursue collaborations with CDMOs like Cellipont Bioservices to co-develop RB-1355 and expand access to BobcatBio’s macrophage-based therapy platform, leveraging their manufacturing capabilities to accelerate clinical progression and broader market reach.

Targeted Tumor Agnostic Highlight the platform’s modularity and lack of reliance on predefined tumor antigens to attract pharma and biotech partners seeking broad applicability across solid tumors, enabling multi-indication license deals and long-term value.

Clinical-Stage Leverage Position BobcatBio as a clinical-stage, capital-efficient partner with a compelling value proposition for joint ventures or out-licensing, given recent collaboration activity and measurable preclinical efficacy signals suggesting faster path to proof-of-concept.

Funding & Growth Emphasize existing funding and modest revenue to attract co-investors and strategic alliances; propose grant collaborations, milestone-based funding, or milestone-driven partnerships to de-risk early-stage development and scale operations.

Global Manufacturing Explore international manufacturing partnerships to expand geographic access, reduce logistics risk, and support multinational trials, leveraging the CDMO collaboration model to establish a robust supply chain for macrophage-based therapies.